These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 16299629

  • 21. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
    van der Veen WJ, van der Werf GT.
    Ned Tijdschr Geneeskd; 2006 May 06; 150(18):1016-21. PubMed ID: 16715866
    [Abstract] [Full Text] [Related]

  • 22. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
    Elnachef N, Scheiman JM, Fendrick AM, Howden CW, Chey WD.
    Aliment Pharmacol Ther; 2008 Nov 15; 28(10):1249-58. PubMed ID: 18729848
    [Abstract] [Full Text] [Related]

  • 23. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 15; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 24. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW.
    Ned Tijdschr Geneeskd; 2004 Oct 30; 148(44):2162-4. PubMed ID: 15559407
    [Abstract] [Full Text] [Related]

  • 25. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
    Dai C, Stafford RS, Alexander GC.
    Arch Intern Med; 2005 Jan 24; 165(2):171-7. PubMed ID: 15668363
    [Abstract] [Full Text] [Related]

  • 26. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May 24; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

  • 27. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 24; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 28. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
    Giannitsis E.
    Clin Lab; 2005 Nov 24; 51(1-2):63-83. PubMed ID: 15719708
    [Abstract] [Full Text] [Related]

  • 29. Cardiovascular effects of cyclooxygenase-2 inhibitors.
    Brophy JM.
    Curr Opin Gastroenterol; 2007 Nov 24; 23(6):617-24. PubMed ID: 17906437
    [Abstract] [Full Text] [Related]

  • 30. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.
    Schug SA, Joshi GP, Camu F, Pan S, Cheung R.
    Anesth Analg; 2009 Jan 24; 108(1):299-307. PubMed ID: 19095866
    [Abstract] [Full Text] [Related]

  • 31. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.
    Am J Cardiol; 2007 Jan 01; 99(1):91-8. PubMed ID: 17196469
    [Abstract] [Full Text] [Related]

  • 32. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF, Buchanan WW.
    Inflammopharmacology; 2005 Jan 01; 13(4):343-70. PubMed ID: 16354389
    [Abstract] [Full Text] [Related]

  • 33. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
    Sun SX, Lee KY, Bertram CT, Goldstein JL.
    Curr Med Res Opin; 2007 Aug 01; 23(8):1859-66. PubMed ID: 17605893
    [Abstract] [Full Text] [Related]

  • 34. [Is there a future for COX-2 inhibitors?].
    Yodfat Y.
    Harefuah; 2004 Nov 01; 143(11):820-4, 837. PubMed ID: 15603272
    [Abstract] [Full Text] [Related]

  • 35. COX-2 inhibitors and the heart: are all coxibs the same?
    Sooriakumaran P.
    Postgrad Med J; 2006 Apr 01; 82(966):242-5. PubMed ID: 16597810
    [Abstract] [Full Text] [Related]

  • 36. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK, Abraham NS, Scheiman JM, Laine L, First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Am J Gastroenterol; 2008 Nov 01; 103(11):2908-18. PubMed ID: 18853980
    [Abstract] [Full Text] [Related]

  • 37. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B, Renner B, Brune K.
    Nat Clin Pract Rheumatol; 2007 Oct 01; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [Abstract] [Full Text] [Related]

  • 38. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D.
    Thromb Haemost; 2006 Oct 01; 96(4):407-12. PubMed ID: 17003915
    [Abstract] [Full Text] [Related]

  • 39. The safety of rofecoxib.
    Burnier M.
    Expert Opin Drug Saf; 2005 May 01; 4(3):491-9. PubMed ID: 15934855
    [Abstract] [Full Text] [Related]

  • 40. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A, Ferrandez A.
    Chin J Dig Dis; 2006 May 01; 7(3):127-33. PubMed ID: 16808792
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.